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Abstract: Currently, no pharmaceuticals for the etiological treatment of degenerative protein-misfolding diseases (e.g., 
ALS, Alzheimer’s or prion diseases) are commercially available. In this technical note theoretical considerations and prac-
tical approaches concerning the development of chaperone-based medications from medicinal plants (e.g., Ginkgo biloba) 
are reviewed and discussed in detail. Phytochaperones and other agents isolated from medicinal plants are proposed to 
serve as the general basis of drug development in protein-misfolding diseases. 
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INTRODUCTION  
  “Nature is, after all, the only book that offers important 
content on every page” (Johann Wolfgang von Goethe, 
1749-1832). This aphorism of the famous poet and natural 
scientist reflects that we should consider all natural sources 
for answers to problems concerning human health and wel-
fare. Medicinal plants, for example, may be important op-
tions for developing drugs for the treatment of different dis-
eases. 
  Despite enormous economical, technical and scientific 
progress in past years, fundamental development of effective 
treatments for several progressive degenerative and neurode-
generative diseases (e.g., amyotrophic lateral sclerosis 
(ALS), Alzheimer’s disease (AD), or Parkinson’s disease, 
etc.) is in its infancy. Many of these diseases are caused by 
the misfolding of one or more important proteins. 
  It is a well-known fact that chemical and pharmacologi-
cal chaperones have been found to be effective in preventing 
the misfolding of different disease-causing proteins. How-
ever, many of these compounds are highly toxic, reveal a 
lack of specificity, or have unknown mechanisms of action 
in vivo. This technical note introduces a new class of phar-
macologically active proteins, namely the (metallo-) phyto-
chaperones, as possibly key molecules for the etiological 
treatment of protein-misfolding diseases (PMD). 
MEDICINAL PLANTS AND PROTEIN-MISFOLDING 
DISEASES 
  Drug discovery from medicinal plants is a challenging 
field because it involves a multifaceted approach combining 
botanical, phytochemical, biological, and analytical tech-
niques [1-36]. Well-known plants used in Traditional Chi-
nese Medicine (TCM), Japanese, Ayurvedic and European 
Medicine relevant to the management of AD and other cog-
nitive disorders are listed in Table 1 [1, 16, 17, 25, 31]. For  
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example, standardized plant extracts from green leaves of the 
Ginkgo biloba tree are generally accepted in the treatment of 
AD [2, 3, 9, 16, 19, 31]. Through the antioxidant properties 
of their flavonoids these extracts may be able to protect hip-
pocampal cells against toxic effects induced by amyloid ß 
(Aß) peptides [2]. An increase in the activity of the antioxi-
dant enzymes, catalase and superoxide dismutase (SOD) 
were further observed in rats treated with EGb 761 Ginkgo 
extract [3]. Another plant used in Ayurvedic medicine, 
termed Bacopa monniera, reduces Aß deposits in brains of 
AD model animals [7]. 
  AD and many other neurodegenerative diseases are asso-
ciated with disturbances of metal ion metabolisms and oxida-
tive stresses postulated to be a downstream effect of abnor-
mal Aß - metal ion interactions [6, 14, 20, 21, 24, 26]. There-
fore, the metal ion homeostasis in a cell is strictly regulated 
by metallochaperones and other biomolecules (e.g., metal-
lothioneins). For example, copper chaperones for superoxide 
dismutase (CCS) are essential metalloproteins for protecting 
and guiding copper ions to superoxide dismutase (SOD). 
Specific protein-protein interactions activate SOD by incor-
porating a Cu
+ ion. As properly folded SOD molecules are 
very important antioxidants, these metal species contribute to 
a decreasing oxidative stress in cells [15, 20, 21, 28]. Thus, 
metal chelators and antioxidants may be therapeutic against 
neurodegenerative diseases [5, 6, 9, 14, 24]. (See especially 
the insightful review by Rochet [32].) 
  Despite several therapeutic approaches, no preventive 
measure or effective treatment for PMD, especially Alz-
heimer’s disease, is currently available [26]. Furthermore, 
vast majorities of psychoactive drugs are not natural prod-
ucts or are not derived from bioactive constituents of me-
dicinal plants [25]. This has led some researchers to recom-
mend the use of natural plant extracts in seeking possible 
protective agents of brain aging [2] and dementia therapy 
[31]. 
  Plant extracts are multicomponent mixtures consisting of 
bioactive main and secondary plant compounds which may 
interact with each other in a synergistic manner [8, 12, 19]. Phytochemical Approach and Bioanalytical Strategy to Develop  The Open Biochemistry Journal, 2008, Volume 2    45 
Drying and storing of medicinal plants are critical steps in 
the production processes of natural extracts and phytomedi-
cines because the chemical stability of the bioactive ingredi-
ents may be adversely affected by the formation of unwanted 
artefacts [4]. As nature is the best combinatorial chemist and 
possibly has answers to all diseases of mankind [17] it is 
assumed that pharmacologically active ingredients in addi-
tion to the well-known plant flavonoids and terpenoids, 
namely proteins and enzymes, could be isolated and identi-
fied in medicinal plants for the effective treatment of several 
PMD (see Table 1). 
  A majority of PMD are considered to be caused primarily 
by an imbalance between pro-oxidant and antioxidant ho-
meostasis [34]. An ideal therapeutic drug to dissolve Aß 
amyloid in AD, for example, would involve a compound 
selective for Cu
1+, Zn
2+ and Fe
3+, but that does not sequester 
Mg
2+ and Ca
2+ [6]. For example, Cu chaperones are a ubiqui-
tous class of proteins that play a significant role in both Cu 
delivery and cellular protection against copper exposure un-
der normal metabolic conditions by delivering and binding 
metal ions [15, 28]. Therefore, bioactive Cu chaperones may 
be the basis for developing novel lead molecules in the 
treatment of PMD. 
  It is a well-known fact that improperly folded copper 
chaperones for superoxide dismutase (CCS) may play an 
important role in the etiology of AD and other PMD. There-
fore, the dysregulation of metal ion homeostasis and severe 
oxidative stresses in bioorganisms may occur in these dis-
eases [20, 21]. Furthermore, under non-physiological condi-
tions a reduced enzyme activity of SOD and apo-SOD 
(apoenzymes) can be detected and quantified in the blood of 
animals [36]. The apoenzymes are referred to as unfolded 
molecules. Therefore, it may be a necessary and helpful 
therapeutic approach to balance the metal ion homeostasis by 
activating unfolded SOD in blood of diseased bioorganisms. 
For these purposes, exogenous plant copper chaperones for 
SOD (pCCS) isolated from medicinal plants may be the lead 
molecules for an effective treatment of PMD. The pCCS 
activators may be able to recover the balance between pro-
oxidant and antioxidant homeostasis of bioorganisms by 
copper ion transfer affecting the mechanism and speed of 
folding for the rapid achievement of the bioactive 3D con-
formation of human SOD (hSOD) and by binding uncom-
plexed metal ions (e.g., Cu
1+, Zn
2+ or Fe
3+) in blood or other 
biofluids of living organisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Workflow schemes in metalloproteomics and interactom-
ics. 
Table 1.  Traditional Medicinal Plants Used for Cognitive Disorders 
Medicinal Plant  Uses, Pharmaceutical and Clinical Effects 
Centella asiatica L  Strengthens nervous function and memory, enhancement of cholinergic activity and thus, cognitive function. 
Ginkgo biloba L  Improvement of memory loss associated with blood circulation abnormalties, favourable effects on neuronal cell 
metabolism, antioxidant activity, neuroprotective against -amyloid toxicity in vitro. 
Melissa officinalis L  Treatment of depression, hysteria and nervous insomnia, shows antioxidant effects. 
Polygala tenuifolia Willd  Used in TCM as a cardiotonic and cerebrotonic, as a sedative and tranquillizer, and for amnesia, forgetfulness, neuri-
tis, nightmares and insomnia. 
Salvia lavandulaefolia Vahl. 
Salvia officinalis L 
Salvia miltiorrhiza Bung 
Cholinesterase inhibition, antioxidant and oestrogenic activities in vitro. 
Treatment of blood circulation disorders, insomnia, neurasthenia and alleviation of inflammation. 
Withania somnifera (L) Dun  Important herb in Ayurvedic medicine, treatment of inflammatory conditions, such as arthritis. 
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DEVELOPMENT OF CHAPERONE-BASED MEDI-
CATIONS 
  For developing chaperone-based medications from me-
dicinal plants the following procedures could be very prom-
ising. For these purposes, properly and improperly folded 
copper cofactor-containing chaperones for superoxide dis-
mutase present in blood samples of AD patients and 
probands have to be purified and their structures elucidated. 
Improperly folded and bioactive metallochaperone proteins 
present in diseased or healthy blood can be resolved in elec-
trophergrams due to their different isoelectric points [18, 20, 
21]. Bioactive and inactive metalloproteins can also be iso-
lated and quantified in other organisms, e.g., model plants by 
using the same methods [20-23]. In Fig. (1) the basic inves-
tigational steps of selected protein-protein interactions and 
metalloprotein detection procedures in complex biological 
systems are schematically presented. 
  By incubating clinical biofluids (e.g., whole blood) with 
medicinal plant extracts (e.g.,  Ginkgo biloba), specific 
apoenzymes in a pathological blood sample (apo-SOD) 
might fold into their native conformation due to specific pro-
tein-protein interactions. Human SOD is a biomacro-
molecule with a molecular mass of about 32 kDa and might 
interact with the investigated plant CCS provided that pCCS 
has a similar molecular mass and structure and function 
compared to human CCS. The respective physiological ef-
fects can be studied using the workflow schemes of Fig. (1). 
  Plant extracts may be obtained by homogenising leaves 
of medicinal plants in liquid nitrogen. Pulverized samples 
may be stored above liquid nitrogen or extracted directly. 
Medicinal plant extracts are prepared under non-denaturing 
conditions by using a buffer such as 20 mM Tris-HCl, pH 
7.2. Plant material and buffer solution may be homogenised 
in a ratio of 1:10 (w/w). After centrifugation of the ho-
mogenate the resultant supernatant is used for merging plant 
extract and blood. The incubation time is extended to a 
maximum of about 15 to 60 minutes at 4° C to avoid uncon-
trolled proteolytic processes, protein precipitation, and de-
stabilization of metal cofactor-containing proteins in this 
very complex system consisting of plant and human matri-
ces. Next, an aliquot of the protein mixture is chromatogra-
phed on a Sephadex G-50 SF size-exclusion column.  
Specific metal cofactor-containing proteins CCS and SOD 
have been found in a narrow peak (MW  30 kDa) as shown 
in Fig. (2). 
  After chromatography, fractions with the highest Cu con-
centration can be separated by an orthogonal procedure to 
resolve the peak components. A procedure that has shown 
promise for this kind of secondary fractionation is quantita-
tive preparative native continuous polyacrylamide gel elec-
trophoresis (QPNC-PAGE) [21]. With QPNC-PAGE, 
physiological amounts of properly folded hSOD and pCCS 
may be isolated in a few specific PAGE fractions. Further-
more, the respective Cu cofactors of these biomolecules can 
be detected in the resultant electropherogram by mass-
spectrometric methods. The complementary QPNC-PAGE 
parameters of CCS and SOD have been listed in various arti-
cles or protocols [20-23, 33]. The ratio of peak areas of the 
copper species may indicate whether certain medicinal plants 
contain bioactive pCCS upon comparison of untreated and 
treated blood from AD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chromatogram showing the UV absorption profile ( = 254 nm) of Arabidopsis supernatant separated on Sephadex G-50 Superfine. 
Gel volume: 500 mL; column length: 700 mm; column diameter: 30 mm; eluent flow rate: 12 mL / hr; fraction volume: 8.0 mL; number of 
fractions: 95; sample volume: 5 mL; separation temperature: 4 °C; elution buffer: 20 mM Tris-HCl, 1 mM NaN3; pH 8.0. The peripheral 
tools used for preparative native GPC are listed in [23, 35]. The denoted molecular weights of the detected metal compounds (MW  30 kDa) 
are approximated values. Metal cofactors eluted in the range of the void volume (120 to 140 mL) of this method were identified and quanti-
fied by ICP-MS or GF-AAS [23, 35]. 
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  In order to develop chaperone-based medications from 
medicinal plants, highly purified pCCS may be further iso-
lated and identified after the QPNC-PAGE run using a com-
bination of 2-D PAGE (2-DE) followed by matrix-assisted 
laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF) and bioinformatics (Fig. (3)). The limitations 
of current proteomics technologies as related to MALDI-
TOF and 2-DE are reviewed in [13]. An approach for identi-
fying a high molecular mass metal protein in the model plant 
Arabidopsis thaliana by using these efficient methods is pre-
sented in [35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Workflow schemes in metalloproteomics and plant mo-
lecular farming. 
 
  The amino acid sequences of identified bioactive metal-
lochaperone proteins in medicinal plants will provide the 
DNA sequence information necessary for their effective pro-
duction by “molecular farming” techniques (Fig. (3)). Plant 
molecular farming is a challenging, new and promising tech-
nique using transgenic plants to produce foreign proteins as 
pharmaceutical ingredients. For these purposes plant growth 
and metabolism has to be optimized under standardized con-
ditions in order to maximize protein concentrations in roots 
and shoots [29]. It is important to mention that this method is 
an alternative to the microbial expression systems enabling 
the correct folding of recombinant proteins [11, 30]. Of 
course, many other clinical and pharmaceutical approaches 
as already described in literature [1 – 36] have to be used for 
development of chaperone-based medications. 
CONCLUSIONS AND OUTLOOK 
  In this technical note, it is proposed that metallochaper-
ones from medicinal plants may provide treatments for pro-
tein misfolding diseases (e.g., Alzheimer’s disease) and ana-
lytical steps are presented by which to test this conjecture. In 
particular, plant copper chaperones for superoxide dismutase 
(pCCS) could very well be the sources for the etiological 
treatment of protein-misfolding diseases, because pCCS may 
have the ability to activate human apo-superoxide dismutase 
(hSOD) in biofluids. The interaction between pCCS and apo-
SOD in human beings and animals may be important for 
recovering the metal ion homeostasis and balance between 
pro-oxidative and antioxidative processes in the cells of 
these organisms. Therefore, this approach could help to pre-
vent or minimize abnormal protein-misfolding processes and 
subsequent oxidative stresses occuring in bioorganisms. 
  In addition to the well-known medicinal plants, e.g., 
Ginkgo biloba, other “living fossils” should be evaluated 
with respect to chelating and antioxidative properties in cells 
concerning the effective treatment of protein-misfolding dis-
eases. For example, giant trees known as California Red-
woods (e.g., Sequoia sempervirens), might be the natural 
sources of active metallochaperones or other important metal 
species. 
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